A new drug called bepirovirsen has achieved a functional cure in about 20% of chronic hepatitis B patients in late-stage trials, raising hopes for a treatment that could end the need for lifelong antiviral therapy.
A new drug named bepirovirsen, commonly referred to as bepi, has demonstrated promising results in clinical trial s for the treatment of chronic hepatitis B, offering what researchers describe as a " functional cure " for a subset of patients.
The drug, developed by GSK and Ionis Pharmaceuticals, works by targeting the hepatitis B virus's genetic material and a key surface protein, thereby suppressing viral replication and enhancing the immune system's ability to control the infection. In two large-scale studies published in the New England Journal of Medicine, approximately 20% of patients who received bepi for six months, followed by an additional six-month observation period, maintained undetectable virus levels after discontinuing all therapy.
This outcome-defined as a functional cure-was not observed in any patient who received a placebo. The U.S. Food and Drug Administration is currently reviewing bepirovirsen, with a decision anticipated by October. Chronic hepatitis B affects over 250 million people globally and leads to severe complications such as liver cirrhosis, liver failure, and liver cancer, causing an estimated 1.1 million deaths annually.
Standard existing therapies can suppress the virus but rarely achieve a durable cure, as hepatitis B often rebounds when treatment stops. Bepirovirsen's mechanism involves binding to viral RNA to block production of new virus particles and the surface antigen, which helps the virus evade immune detection. The clinical trials involved 1,838 participants who received either weekly injections of bepi or a placebo for six months, alongside their usual antiviral pills.
After the treatment phase, patients who had undetectable hepatitis B DNA for at least six months were permitted to stop all medication. The 20% success rate represents a significant milestone in hepatitis B research, a field that has long sought a functional cure. The drug's potential to reduce or eliminate the need for lifelong antiviral therapy could transform management of the chronic disease.
Hepatitis B is transmitted through contact with infected blood or bodily fluids and can be prevented by vaccination. Many infected individuals experience no symptoms during acute infection, but chronic infection can remain asymptomatic for decades before causing progressive liver damage. The Centers for Disease Control and Prevention emphasizes that while treatments can control viral load, they do not eradicate the virus from the body. Bepirovirsen's ability to induce sustained viral suppression after treatment cessation marks a novel therapeutic approach.
If approved, bepi would become the first drug to offer a functional cure for a meaningful proportion of chronic hepatitis B patients. The results have been met with cautious optimism from experts, who note that longer-term follow-up is needed to confirm durability of response. The drug's safety profile and potential side effects also require careful consideration.
With FDA review underway, the medical community awaits a decision that could signal a new era in hepatitis B management, moving beyond suppression toward potential cure. The studies were funded and conducted by GSK and Ionis Pharmaceuticals, and the data were independently validated by researchers.
This breakthrough highlights the importance of targeting viral gene expression as a strategy to overcome the persistence of hepatitis B. For the millions living with chronic hepatitis B, the prospect of ending lifelong treatment offers hope for improved quality of life and reduced risk of liver-related complications
Hepatitis B Bepirovirsen Functional Cure GSK Ionis Pharmaceuticals Clinical Trial FDA Antiviral Liver Disease Viral Suppression
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Experimental hepatitis B drug might offer 'functional cure' for a subset of patientsNew research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus.
Read more »
Experimental hepatitis B drug might offer 'functional cure' for a subset of patientsNew research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus.
Read more »
Experimental hepatitis B drug might offer 'functional cure' for a subset of patientsNew research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus.
Read more »
Experimental hepatitis B drug may offer 'functional cure' for some patientsNew research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus.
Read more »